HIT Consultant May 22, 2024
What You Should Know:
– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.
– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.
Strengthening the DTx Pipeline
The acquisition includes several key assets from Better Therapeutics:
- AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.
- BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).
- BT-002: A DTx designed to reduce blood pressure in patients with hypertension.
- BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.
The strategic acquisition significantly expands Click’s DTx...
Today's Sponsors
Today's Sponsor